Passage BIO, Inc. (PASG)
D
Pipeline Grade
Financial Position (from SEC Filings)
$33.3M
Cash & Equivalents
$13.0M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$15M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | OTHER | Enrolling By Invitation | 100,000 |
| NCT03047369 | The Myelin Disorders Biorepository Project | OTHER | Recruiting | 12,000 |
| NCT04747431 | A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes | PHASE2 | Active Not Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-24 | 8-K | Passage BIO, Inc. (PASG) (CIK 0001787297) - EXHIBIT 99.2 | EDGAR |